Aeon Biopharma Class A (AEON) closed at $0.23 on October 22, 2026, down 2.6% from the previous close, on volume of 104,225 shares (30-day average 13,056,209).
Data as of October 22, 2026.
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Globe Newswire (Fri, 9-Oct 4:15 PM ET)
AEON climbs as FDA Type 2b feedback supports a potentially streamlined ABP-450 biosimilar path
Market Chameleon (Wed, 30-Sep 7:36 AM ET)
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
Globe Newswire (Wed, 30-Sep 8:00 AM ET)
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
Globe Newswire (Mon, 31-Aug 8:00 AM ET)
Market Chameleon (Tue, 25-Aug 6:31 AM ET)
Globe Newswire (Mon, 24-Aug 8:00 AM ET)
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX
Globe Newswire (Wed, 19-Aug 8:00 AM ET)
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 12-Aug 4:15 PM ET)
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
Globe Newswire (Mon, 3-Aug 4:15 PM ET)
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
Aeon Biopharma Class A trades on the AMEX stock market under the symbol AEON.
As of October 22, 2026, AEON stock price declined to $0.23 with 104,225 million shares trading.
AEON has a beta of 0.58, meaning it tends to be less sensitive to market movements. AEON has a correlation of 0.00 to the broad based SPY ETF.
AEON has a market cap of $11.66 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AEON traded as high as $1,236.24 and as low as $.18.
The top ETF exchange traded funds that AEON belongs to (by Net Assets): VXF.
AEON has underperformed the market in the last year with a price return of -79.3% while the SPY ETF gained +14.9%. AEON has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.9% and -24.9%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
AEON support price is $.22 and resistance is $.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEON shares will trade within this expected range on the day.
